Latest Period
Q4 2025
CUSIP: 74346M406
Latest Period
Q4 2025
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$0.42
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
Latest holder context comes from 0 institutions filings for Q4 2025.
What is CUSIP 74346M406?
CUSIP 74346M406 identifies PMN - PROMIS NEUROSCIENCES INC. - Common Shares in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Use the next link that matches the question you still need to answer about this security.
Open recent reporting periods for CUSIP 74346M406:
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Shaf QIC LLC | 10% | $5,096,658 | 10,534,639 | Shaf QIC LLC | 29 Jul 2025 | |||
| Sclar Jeremy M. | 17% | $3,804,772 | 9,511,930 | Jeremy M. Sclar | 30 Sep 2025 | |||
| ABG Management Ltd. | 11% | 0% | $2,549,570 | 6,070,405 | 0% | ABG Management Ltd. | 29 Jan 2026 | |
| GREAT POINT PARTNERS LLC | 10% | 0% | $2,547,215 | +$1,125,043 | 5,972,369 | +79% | Great Point Partners, LLC | 30 Sep 2025 |
| GORDON MICHAEL S | 9% | $2,363,899 | 4,886,108 | Michael S. Gordon | 30 Jun 2025 | |||
| JANUS HENDERSON GROUP PLC | 14% | $542,958 | 1,292,757 | JANUS HENDERSON GROUP PLC | 31 Mar 2026 | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% | $376,268 | 895,877 | Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 11 Mar 2026 | |||
| ARMISTICE CAPITAL, LLC | 0.93% | -77% | $211,963 | -$1,037,335 | 504,673 | -83% | Armistice Capital, LLC | 31 Dec 2025 |
| SPHERA FUNDS MANAGEMENT LTD. | 7.8% | +38% | $75,893 | -$1,235,385 | 180,698 | -94% | Sphera Funds Management Ltd. | 31 Dec 2025 |
As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of PROMIS NEUROSCIENCES INC. - Common Shares (PMN). This represents 0% of the company’s total 8,977,479 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$4,247,586 | $0.42 | 0 |
| 2025 Q3 | 9,993,894 | $4,247,586 | +$501,350 | $0.42 | 23 |
| 2025 Q2 | 8,473,099 | $4,101,148 | -$540,895 | $0.48 | 19 |
| 2025 Q1 | 9,325,986 | $6,489,664 | -$305,401 | $0.70 | 17 |
| 2024 Q4 | 9,747,253 | $9,238,269 | -$516,735 | $0.95 | 18 |
| 2024 Q3 | 10,087,669 | $12,611,608 | +$8,040,363 | $1.25 | 18 |
| 2024 Q2 | 3,232,221 | $4,848,022 | -$221,623 | $1.50 | 15 |
| 2024 Q1 | 3,382,907 | $6,463,092 | +$75,871 | $1.91 | 16 |
| 2023 Q4 | 3,347,909 | $3,849,710 | +$624,784 | $1.15 | 13 |
| 2023 Q3 | 2,804,768 | $5,609,387 | +$5,238,947 | $1.98 | 13 |
| 2023 Q2 | 186,447 | $723,079 | -$4,625 | $3.88 | 12 |
| 2023 Q1 | 187,649 | $888,276 | -$5,905 | $4.73 | 11 |
| 2022 Q4 | 189,088 | $823,550 | +$19,204 | $4.34 | 12 |
| 2022 Q3 | 184,593 | $1,130,000 | +$1,129,000 | $6.08 | 11 |
| 2022 Q2 | 10,000 | $1,000 | +$1,000 | $0.10 | 1 |